Key statistics
52-week range
Short selling activityProvided by S&P Global Market Intelligence
| Open | 1.50 |
|---|---|
| High | 1.42 |
| Low | 1.42 |
| Bid | 1.40 |
| Offer | 1.47 |
| Previous close | 1.49 |
| Average volume | 12.88k |
|---|---|
| Shares outstanding | 93.74m |
| Free float | 67.19m |
| P/E (TTM) | -- |
| Market cap | 139.86m EUR |
| EPS (TTM) | -0.5497 EUR |
Data delayed at least 20 minutes, as of Feb 06 2026 14:25 GMT.
More ▼
- Number of Shares and Voting Rights of Innate Pharma as of December 31, 2025
- Number of Shares and Voting Rights of Innate Pharma as of December 18, 2025
- Innate Pharma Releases Its 2026 Financial Calendar
- Number of Shares and Voting Rights of Innate Pharma as of November 27, 2025
- Innate Pharma to Present at Jefferies Global Healthcare Conference
- Innate Pharma Reports Third Quarter 2025 Business Update and Financial Results
- Innate Pharma Announces FDA Clearance to Proceed With TELLOMAK 3, a Confirmatory Phase 3 Trial of Lacutamab in CTCL
More ▼
